Secondary Hyperparathyroidism - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Secondary Hyperparathyroidism - Pipeline Review, H1 2019’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism

- The report reviews pipeline therapeutics for Secondary Hyperparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Secondary Hyperparathyroidism therapeutics and enlists all their major and minor projects

- The report assesses Secondary Hyperparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Takeda Pharmaceutical Co Ltd

Amgen Inc

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Secondary Hyperparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development

Amgen Inc

EA Pharma Co Ltd

Lupin Ltd

Mitsubishi Tanabe Pharma Corp

OPKO Health Inc

Takeda Pharmaceutical Co Ltd

Secondary Hyperparathyroidism - Drug Profiles

AJT-240 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcifediol ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinacalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinacalcet hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTA-091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dendocrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etelcalcetide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evocalcet - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LNP-1892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary Hyperparathyroidism - Dormant Projects

Secondary Hyperparathyroidism - Discontinued Products

Secondary Hyperparathyroidism - Product Development Milestones

Featured News & Press Releases

Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients

Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology

Aug 31, 2017: European Commission Approves Expanded Use Of Mimpara (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis

Jun 23, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD

Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE

Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan

Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis

Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer

Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis

Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan

Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development ...

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H1 2019

Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H1 2019

Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H1 2019

Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019

Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H1 2019

Secondary Hyperparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Secondary Hyperparathyroidism - Dormant Projects, H1 2019

Secondary Hyperparathyroidism - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports